Our Research

Health Economics

Our center evaluates the economic value of health interventions to inform smarter allocation of resources. We focus on cost-effectiveness analyses of vaccines, therapeutics, and preventive strategies, quantifying both health impact and financial efficiency. By integrating epidemiological modeling with economic evaluation, we help identify interventions that deliver the greatest benefit for the investment—guiding decisions that reduce disease burden while optimizing healthcare spending.

Recent Works

Pricing RSV Vaccines for Maximum Value

Our analysis shows that compared with no vaccination, prefusion F protein–based RSV vaccines for U.S. adults aged 60+ can be cost-effective at prices up to about $120 per dose, and higher if protection lasts more than one season.

See more

Boosting Coverage Delivers Big Benefits: Fewer Cases, Lower Costs

Our modeling shows that compared to maintaining baseline booster uptake, a high‑uptake bivalent booster campaign in NYC (January–March 2023) would have averted tens of thousands of COVID‑19 cases and nearly 3,000 hospitalizations, saved over $200 million in direct healthcare costs, and reduced student absenteeism substantially

See more

New York City’s COVID-19 Vaccination Delivered $10.19 Back for Every Dollar Spent

Our modeling shows that compared to a scenario without vaccination, NYC’s COVID‑19 vaccination campaign generated approximately $52 billion in net savings—averting nearly $28 billion in direct healthcare costs and $26 billion in value-of-statistical-life and productivity losses—translating to a return of about $10 for every $1 spent

See more
Full Publications

Recent Media Coverage

So worth it: COVID vaccination generated tenfold return on investment in New York
Vaccinating against COVID-19 saves lives. It can also save healthcare systems considerable amounts of money, study finds.
www.gavi.org
What was the return on investment of the COVID-19 vaccination campaign in New York City?
A recent study estimated the return on investment (ROI) of New York City’s coronavirus disease 2019 (COVID-19) vaccination campaign.
www.news-medical.net
Adapt the frequency of COVID-19 testing depending on transmission rate and community immunity, study finds | ScienceDaily
Expanding rapid testing stands out as an affordable way to help mitigate risks associated with COVID-19 and emerging variants. Infectious disease researchers have developed a new model that tailors testing recommendations to new variants and likely immunity levels in a community, offering a new strategy as public health leaders seek a way out of a pandemic that has so far thwarted the best efforts to end its spread.
www.sciencedaily.com
Yale Study Says Medicare for All Would Save U.S. $450 Billion, Prevent Nearly 70,000 Deaths a Year | Democracy Now!
www.democracynow.org
New study identifies cost-effective way to reduce death due to rabies
Every year in India, 20,000 people are estimated to die from rabies. Most of the victims are children. Nearly all of the deaths occur after victims are bitten by rabid dogs. For years, experts have debated the best strategy to reduce this burden.
www.news-medical.net

Resources and Tools